Navigation Links
Biomedical Research Centre developing enhanced cells as therapies
Date:9/2/2009

An increased understanding of the role of the body's immune system in the development of diseases such as prostate cancer, squamous cell carcinoma (a type of skin cancer), type 1 diabetes, autoimmune liver disease, and in the rejection of transplanted organs by some transplant patients, has paved the way for a pioneering research programme which aims to develop 'enhanced' cells as therapies. Researchers hope to find ways to extract specific cells which play a role in these diseases from patients, then activate or modify them in the laboratory and transfer them safely back into patients so that they can fight the diseases from within their own body.

The 1 million research programme is being carried out at the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC) at Guy's and St Thomas' and King's College London, working in partnership with King's College Hospital. Researchers expect to conduct the first clinical trials in patients within the next few years, manufacturing these 'enhanced' cells in new licensed premises at Guy's Hospital.

Their work will focus on the cells which cause unwanted immune responses in the development of conditions such as type 1 diabetes, autoimmune liver disease and transplant rejection, as well as the cells that do not respond adequately in preventing certain cancers from developing.

Professor Mark Peakman, Infection and Immunity theme lead within the BRC, said: "One of the problems we face in the quest to improve treatments for diseases such as prostate cancer and squamous cell carcinoma, is how we can get the immune system to respond in the way we need it to - to stop tumour growth. On the other hand, in conditions such as type 1 diabetes and transplant rejection, the immune system is over-active. If we can find ways to prevent the immune response that leads to the death of insulin-producing cells we could find a new way to treat diabetes. Likewise, if we can prevent the immune system of a transplant patient recognising and reacting to a 'foreign' donated organ, we may be able to improve long-term transplant success."

The cells researchers will be focusing on are:

  • gamma delta T cells in the fight against prostate cancer tumour development
  • chimaeric antigen receptor-grafted T cells for squamous cell carcinoma
  • islet-specific Treg cells for type 1 diabetes
  • hepatocyte specific Treg cells for autoimmune liver disease
  • alloantigen-specific Treg cells in organ transplantation.

These cells have been selected as targets because scientific research has already shown their importance to the underlying biological processes involved in the development of these diseases.

Working with blood samples, the researchers aim to find ways to extract these cells, activate them or gene modify them in sufficient quantities to provide effective treatments. They will seek to identify methods to achieve this in a laboratory setting, and then to assess whether they can safely control and manage the manufacture of these novel cell-based therapies so they can be tested in patients. By taking this step-by-step approach, they will assess the clinical feasibility of using these 'enhanced' cells as therapeutic agents and put those believed to be most effective forward for clinical trials.

Key to the success of this programme will be the application of leading-edge cell selection systems and use of new Good Manufacturing Practice (GMP) premises within the Clinical Research Facility at Guy's Hospital, which is due to open next year, along with the GMP facility already operating at King's College Hospital.

Professor Frank Nestle, Director of the Clinical Research Facilities said: "We need to find ways to replicate procedures that work in the laboratory in a clinical setting, so that the cells can be manufactured safely in the quantities we need to test them in patients. We look forward to doing this within our hospital environment, in state-of-the-art facilities that are being purpose-built for innovative clinical research."

This research programme is an exciting endeavour for the comprehensive Biomedical Research Centre and for King's Health Partners, one of only five accredited Academic Health Science Centres in the UK, involving King's College London, and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts.

Professor Robert Lechler, Director of King's Health Partners, said: "This research programme will potentially lead to King's Health Partners being among the first to test novel 'enhanced' cell therapies in patients. This is just the kind of translational research that is central to the work of the Biomedical Research Centre and to King's Health Partners research that depends on the active participation of local patients. We certainly benefit hugely from their involvement and they will be the first to benefit from our progress."


'/>"/>

Contact: Andrea Ttofa
andrea.ttofa@gstt.nhs.uk
44-207-188-5577
King's College London
Source:Eurekalert

Related medicine news :

1. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
2. New test for safer biomedical research results
3. Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute
4. 17 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences
5. Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer
6. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
7. New Video Series Spotlights Role of Biomedical Engineers in Caring for Total Artificial Heart Patients
8. Response Biomedical Closes $12.65 million Unit Offering
9. Garth Fisher, M.D., F.A.C.S., World Renowned Plastic Surgeon and Co-Founder Of CellCeuticals(R) Biomedical Skin Treatments Revealed On E!s Keeping Up With The Kardashians as the Surgeon Behind Bruce Jenners New Face
10. Response Biomedical Announces Proposed Unit Offering
11. Dr. Abbott J. Krieger Joins Avery Biomedical Devices, Inc. as Chief Clinical Liaison
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare ... Act. Dr. Botelho advocates for the mass media launching of story movements to ... opportunities to share their unfortunate experiences; such a movement can generate the network ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance and Financial ... in Little Rock, has initiated a charity drive to provide support and funding ... End Senior Hunger, Arkansas ranks first in senior hunger statewide, third in child ...
(Date:12/8/2016)... AL (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Jefferson County, is announcing the ... Woman’s Shelter in Birmingham. , The number of homeless women and children in ...
(Date:12/8/2016)... ... , ... Coppin Insurance Agency, an insurance and financial planning firm based in ... area, is embarking on a charity drive with the goal of providing support and ... Food Bank of Southwest Florida works to provide fresh and nutritious food free of ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... world,s largest abstract and citation database of peer-reviewed literature, providing the ... 5,000 publishers. The new set of metrics will improve decisions on ... adjust a journal,s editorial strategy. ... , CiteScore metrics comprise ...
(Date:12/8/2016)... -- Mederi Therapeutics Inc . hat die behördliche Zulassung durch die ... Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the ... at Wuhan Union Hospital ...
Breaking Medicine Technology: